MicroRNA-429 inhibits bone metastasis in breast cancer by regulating CrkL and MMP-9

Zhang, Xinxin; Yu, Xiying; Zhao, Zhenguo; Yuan, Zhennan; Ma, Peiqing; Ye, Zhibin; Guo, Liping; Xu, Songfeng; Xu, Le; Liu, Ting; Liu, Huanmei; Yu, Shichong

doi:10.1016/j.bone.2019.115139

Cited by 24 publications

(34 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thus, genes in C1 and C2 were more likely to contribute to Lewis lung carcinoma bone metastasis. Consistently, Angiopoietin 1 (ANGPT1) in C1, and MMPs and Endothelin 1 (EDN1) in C2 had been reported to take part in prostate or breast cancer bone metastasis 23,24,37,38 . Several KEGG 39 pathways were significantly enriched in C0, C2 and C4 modules but not C1 and C3, as shown in Figure 1B.…”

Section: Resultsmentioning

confidence: 54%

“…Moreover, miRNA‐33a, targeting PTHrP, is confirmed to reduce bone resorption in NSCLC 20 . In addition, matrix metalloproteinase (MMPs) and their upstream signalling pathways, like transforming growth factor (TGF‐β), Wnt, chemokine (C‐X‐C Motif) receptor 4 (CXCR4) and nuclear factor kappa‐B (NFκB), may also contribute to NSCLC bone metastases via MMPs 5,17,21‐24 …”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

BMP2 signalling activation enhances bone metastases of non‐small cell lung cancer

Huang

Yun

et al. 2020

J Cellular Molecular Medi

View full text Add to dashboard Cite

Distant metastases occur when non‐small cell lung cancer (NSCLC) is at late stages. Bone metastasis is one of the most frequent metastases of NSCLC and leads to poor prognosis. It has been reported that high expression of BMP2 in NSCLC correlates with poor survival, but whether BMP2 contributes to NSCLC bone metastasis remains largely unknown. The activation of BMP signalling is found in metastatic bone tumours of mice Lewis lung carcinoma and predicts poor survival in human NSCLC. BMP2 signalling activation can enhance bone metastasis of Lewis lung carcinoma. Moreover, BMP2 secreted by stroma fibroblasts can promote the migration and invasion of NSCLC cells. Besides, in combination with pre‐osteoblast and LLCs, BMP2 could enhance the differentiation of macrophages into osteoclasts to play roles in the osteolytic mechanism of NSCLC bone metastasis. Interestingly, NSCLC cells can also enrich BMP2 to pre‐osteoblasts to function in the osteoblastic mechanism. Our results firstly demonstrate the detailed mechanisms about what roles BMP2 signalling play in enhancing NSCLC bone metastases. These findings provide a new potential therapy choice for preventing bone metastases of NSCLC via the inhibition of BMP2 signalling.

show abstract

Section: Resultsmentioning

confidence: 54%

Section: Introductionmentioning

confidence: 99%

BMP2 signalling activation enhances bone metastases of non‐small cell lung cancer

Huang

Yun

et al. 2020

J Cellular Molecular Medi

View full text Add to dashboard Cite

show abstract

“…The over-expression of specific miRNAs (e.g. miR-10b, miR-21 and miR-218-5p) or their downregulation (e.g miR-30s, miR-34a, miR-124, miR-125b, miR-135, miR-203, miR-205 and miR-429) in breast cancer cells promotes the formation of metastasis in bone [17,19,23,26,30,[34][35][36][37]40].…”

Section: Discussionmentioning

confidence: 99%

MicroRNAs and Their Roles in Breast Cancer Bone Metastasis

Puppo

Valluru

Clézardin

2021

Curr Osteoporos Rep

View full text Add to dashboard Cite

Bone metastasis occurs in advanced stages of breast cancer, worsening the quality of life and increasing the mortality of patients. Current treatments for bone metastasis are only palliative, and efficient therapeutic targets need to be still identified. MicroRNAs (miRNAs) are a large class of small non-coding RNAs that regulate gene expression within cells. Interestingly, the expression of certain miRNAs has been associated with several stages of bone metastasis progression, highlighting the importance of these small RNAs during the course of the metastatic disease. In this review, we aim to summarise the most recent findings on miRNAs and their mRNA targets in driving breast cancer bone metastasis. Furthermore, we discuss the possibility to use miRNAs as direct therapeutic targets or as advanced therapies for breast cancer bone metastasis, as well as their potential as predictive biomarkers of bone metastasis for an early diagnosis and a better tailoring of therapies for cancer patients.

show abstract

“…Other miRNAs that have emerged as inhibitors of the BM process include miR-429, that has been recently shown to counteract osteoclast differentiation while promoting osteoblastogenesis in vitro, and to restrain skeletal destruction in murine models of BC, by negatively regulating the expression of V-crk sarcoma virus CT10 oncogene homolog-like (CrkL) and MMP-9 genes [77] .…”

Section: Application Of “Omics” Sciences To the Early Identification mentioning

confidence: 99%

Application of “omics” sciences to the prediction of bone metastases from breast cancer: State of the art

Gentile

Centonza

Lovero

et al. 2021

Journal of Bone Oncology

View full text Add to dashboard Cite

show abstract

MicroRNA-429 inhibits bone metastasis in breast cancer by regulating CrkL and MMP-9

Cited by 24 publications

References 52 publications

BMP2 signalling activation enhances bone metastases of non‐small cell lung cancer

BMP2 signalling activation enhances bone metastases of non‐small cell lung cancer

MicroRNAs and Their Roles in Breast Cancer Bone Metastasis

Application of “omics” sciences to the prediction of bone metastases from breast cancer: State of the art

Contact Info

Product

Resources

About